Citations

Clear

1056 citation(s) found for "Sharma, P".

Relationship between aerobic fitness and adipose tissue insulin resistance
Lytle, Kelli A. , Jensen, Michael D. , Sharma, Arunima, Jensen, Michael , Sharma, Arunima

Mayo Clinic

American Journal of Physiology-Endocrinology and Metabolism | November 20, 2025 | Volume: 330 | Issue: 1 | Pages: E81-E87

10.1152/ajpendo.00327.2025 | PMID 41263784 Get It

Greater degrees of aerobic fitness are associated with greater insulin-mediated muscle glucose uptake. Insulin regulates adipose tissue lipolysis, whether aerobic fitness affects insulin’s ability to regulate lipolysis is unknown. We found that greater fitness is associated with improved adipose tissue insulin responsiveness independent of age, sex, BMI, visceral adipose tissue, body fat (kg), percent body fat, and adipocyte size. This suggests that exercise, if it improves fitness, may improve both adipose tissue and muscle function.
The Case of a 28‐Year‐Old Woman With Medically Refractory Focal Epilepsy
Sharma, Rishi , Leppik, Ilo E. , Walczak, Thaddeus S., Patel, Sima , McGovern, Robert A. , Patel, Sima , Henry, Thomas R.

Mayo Clinic

Annals of Clinical and Translational Neurology | November 20, 2025 | Volume: 13 | Issue: 2 | Pages: 418-423

10.1002/acn3.70253 | PMID 41261507 Get It

ABSTRACT We present the case of a 28‐year‐old right‐handed woman with medically refractory focal epilepsy. Her seizure semiology and electroencephalography (EEG) indicated a seizure onset zone in the right central‐parietal area. However, both MRI and PET scans were unremarkable, showing no focal lesions or areas of altered metabolism. Intracranial monitoring, with extensive evaluation of both hemispheres, confirmed the seizure onset zone in the right central‐parietal region. This area not only served as the site of seizure onset but also encompassed the primary sensory cortex.
A lightweight machine learning tool for Alzheimer's disease prediction
Suresh, Vinay , Nahar, Tulika , Sharma, Arkansh, Mohammed, Omer , Mishra, Devansh , Verma, Amogh , Mishra, Ayush, Malhotra, Hardeep Singh , Verma, Amogh , Suresh, Vinay , Sharma, Arkansh, Panchawagh, Suhrud , Mohammed, Omer, Muneer, Muneeb Ahmad , Mishra, Devansh, Sanker, Vivek , Garg, Ravindra Kumar , Mohammed, Omer

Mayo Clinic

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | November 17, 2025 | Volume: 17 | Issue: 4 | Pages: No page available

10.1002/dad2.70187 | PMID 41256012 Get It

Abstract INTRODUCTION Alzheimer's disease (AD) is a progressive neurodegenerative disorder that needs better predictive tools. Using the National Alzheimer's Coordinating Center Uniform Data Set, this study developed machine learning (ML) models and a practical clinical tool for AD prediction. METHODS Data from 52,537 individuals (22,371 with AD) and more than 200 variables were processed with MissForest imputation and genetic algorithm‐based selection. Multiple ML models were trained, and interpretability was performed using SHAP and permutation importance. A LightGBM model was refined through iterative backward feature elimination (IBFE) followed by manual refinement. RESULTS LightGBM performed best (receiver operating characteristic‐area under the curve [ROC‐AUC] 0.91, accuracy 82.0%). Key predictors included arthritis, age, body mass index, and heart rate. A 19‐feature model retained accuracy (81.2%) and ROC‐AUC (0.90). DISCUSSION This lightweight tool predicts AD using mostly routine variables. Limitations include its cross‐sectional nature, and would need external validation. An interactive web app and GitHub resource are available. Highlights Developed a lightweight ML based tool using 19 routinely available features. The lightweight model achieved an ROC-AUC of 0.90 for Alzheimer's disease prediction on NACC multicenter data. Genetic algorithm, IBFE, and manual refinement enabled optimal feature selection. Tool hosted on an open‐access platform for clinical and research use. SHAP analysis provided model interpretability and feature‐level insights.
CSIG-26. SUBTYPE-SPECIFIC SIGNALING LANDSCAPES OF EGFR-G598V AND -A289V REVEAL TARGETABLE VULNERABILITIES IN INVASIVE GLIOBLASTOMA
Weaver, Sidney , Hansen, Nathaniel, Martinez, Melissa , Tuncali, Sedar, Flick, Matthew , Kloss, Jean , Sereduk, Christopher, Hu, Leland , Lavarone, Antonio, Pirrotte, Patrick , Loftus, Joseph C. , Tran, Nhan L. , Tran, Nhan L , Sharma, Ritin , D’Angelo, Fulvio , Tuncali, Sedar, Sereduk, Chris

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v89-v89

10.1093/neuonc/noaf201.0360 Get It

Abstract IDH-wildtype glioblastoma (GBM) is the most malignant primary adult brain tumor, with a five-year survival rate below 5%. Despite maximal treatment, including surgical resection, radiotherapy, and temozolomide (TMZ), recurrence is universal, driven by profound intratumoral heterogeneity, diffuse invasion, and therapy resistance. A hallmark of IDH-wildtype GBM is frequent alteration of epidermal growth factor receptor (EGFR), including amplification (50%), the EGFRvIII deletion variant (25%), and extracellular missense mutations such as G598V and A289V (10–15%). These missense mutations increase ligand affinity and receptor activity, yet their downstream signaling consequences and role in shaping the tumor phenotypes remain poorly defined. Recent pathway-based subclassifications identified four subtypes in IDH-wildtype GBM. Notably, neuronal (NEU) and glycolytic/plurimetabolic (GPM) subtypes predominate the invasive tumor margins. NEU programs are enriched in synaptic and neurodifferentiation signals, while GPM programs are associated with metabolic adaptation, angiogenesis, and immune evasion. Here, we show EGFR-G598V and EGFR-A289V mutations differentially regulate these invasive subtypes identities. Transcriptional analysis reveals EGFR G598V upregulates metabolic and inflammatory pathways consistent with the GPM phenotype, while EGFR A289V activates genes involved in neuronal differentiation and synaptic function, aligning with the NEU subtype. Phosphoproteomics and kinase-substrate analysis further uncovered distinct kinases to be functionally activated/inhibited in EGFR A289V-expressing cells and G598V cells. Mechanistic studies revealed EGFR A289V induces sustained EGFR phosphorylation at Y992, activating PLCγ2 via the SRC-family kinase LCK. This cascade drives calcium release, CAMK1 activation, and STAT5 phosphorylation, defining a novel EGFR A289V–LCK/PLCγ2/CAMK1/STAT5 axis. In addition, Y1068 phosphorylation is also constitutively active in EGFR A289V, resulting in increased BRAF activation. In contrast, EGFR G598V activates MAPK6 and CAMK2 inducing AKT2 activation, reinforcing GPM-associated signaling. These findings uncover mutation-specific signaling networks that drive subtype fate in invasive GBM and highlight unique pathway(s) as tractable targets for subtype-directed therapy in EGFR-mutant GBM.
A Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of a Folate Receptor Alpha Vaccine in Patients with Triple-Negative Breast Cancer
Knutson, Keith L. , Abu‐Fares, Hala , Keating, Peter , Block, Matthew S. , Norton, Nadine , Erskine, Courtney L. , Cogen, Davitte , Assad, Hadeel , Graff, Stephanie L. , Hamilton, Erika , McIntyre, Kristi , Sparano, Joseph A. , Tiersten, Amy , Tkaczuk, Katherine , Wilson, G. Haswell , Garrett, Gerald , Keating, Patricia , Hamilton, Erika P , Han, Hyo S , McIntyre, Kristi J , Nassar, Aziza , Sparano, Joseph A , Tiersten, Amy , Tkaczuk, Katherine H , Ward, Patrick J , Wilson, Glynn , Garrett, Gerald , Kenney, Richard T , Sharma, Priyanka , Knutson, Keith L. , Graff, Stephanie L , Norton, Nadine , Ward, Patrick J. , Sharma, Priyanka

Mayo Clinic

Clinical Cancer Research | November 10, 2025 | Volume: 32 | Issue: 1 | Pages: 106-117

10.1158/1078-0432.ccr-25-2763 | PMID 41213103 Get It

Abstract Purpose: CD4 T-cell immunity is associated with improved survival in patients with breast cancer. We previously reported a phase I trial evaluating a folate receptor alpha (FRα) vaccine administered with cyclophosphamide (CP), demonstrating excellent safety and immunogenicity. To simplify the vaccine strategy for ease of use, we report here the results of a randomized phase II trial evaluating a lower vaccine dose alongside the original dose, administered with or without CP pretreatment. Patients and Methods: Patients with triple-negative breast cancer who completed all systemic and local therapies were assigned to receive either low-dose (825 μg) or high-dose (2.5 mg) vaccine peptides plus GM-CSF in six 4-week cycles, with or without CP prior to vaccination. Safety was monitored, and immunogenicity was evaluated before and after vaccination. Results: A total of 80 patients were dosed with vaccine, and 58 patients were evaluable for immunogenicity. Vaccination was well tolerated and elicited immunity in 83% of patients. Levels of FRα-specific T cells were high, persistent, and comparable with T-cell levels against tetanus toxoid. No differences in immunity were observed between the two doses. CP pretreatment also did not affect the immune responses. Recurrences occurred in eight evaluable patients and were unrelated to the treatment arm. No patients died during the study because of their disease. Conclusions: The reduced-dose FRα vaccine is as effective as the original dose and does not require CP to generate maximal immunity. These findings may inform the design of trials testing efficacy in triple-negative breast cancer or other cancers.
Beyond Alzheimer’s disease—translating biomarker insights across CNS diseases
Brady, Linda S. , Mahinrad, Simin , Edelmayer, Rebecca M. , Potter, William Z. , Hutten, Samantha J. , Anticevic, Alan , Taylor‐Burds, Carol , Winston, Charisse N. , Coetzee, Timothy , Paulsen, Jane S. , Mantua, Valentina, Childers, Eva P. , Jack, Clifford R. , Jagust, William J. , Wagner, John A. , Sivakumaran, Sudhir , Shaw, Leslie M. , Jack, Clifford R , Jagust, William J , Wagner, John A , Sivakumaran, Sudhir , Shaw, Leslie , Mahinrad, Simin , Kolb, Hartmuth C. , Sharma, Vikas Mohan

Mayo Clinic

Science Translational Medicine | November 5, 2025 | Volume: 17 | Issue: 823 | Pages: No page available

10.1126/scitranslmed.adr2511 | PMID 41191776 Get It

Decades of research on biomarker identification and integration in Alzheimer’s disease (AD) have helped to advance biologically driven disease models, disease subtypes, and disease-modifying treatments. Key lessons learned from AD biomarker development include the need for integration of new biological insights, investment in large cross-sectional and longitudinal studies, a multicomponent biomarker approach, and recruitment of clinical trial cohorts and biosamples that are representative of the target population. We describe how these lessons are being applied in Parkinson’s disease, Huntington’s disease, multiple sclerosis, and psychotic disorders as use cases to inform biomarker-based approaches across central nervous system disorders.
Abstract 4373431: Restoring Cardiac Function with His-Purkinje Conduction System Pacing: A Meta-Analysis in Pacemaker-Induced Cardiomyopathy
Sharma, Arundhati , Daid, Simranpreet Singh, Sharma, Anubhuti , Sharma, Saurabh

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4373431 Get It

Background: Chronic right ventricular pacing (RVP) can lead to electrical dyssynchrony, often resulting in pacemaker-induced cardiomyopathy (PICM). Although biventricular pacing (BiVP) is a standard upgrade strategy, it is associated with notable rates of non-response and procedural limitations. Conduction system pacing (CSP), including His bundle pacing (HBP) and left bundle branch pacing (LBBP), offers a more physiological approach by directly engaging the native conduction system. Emerging evidence supports the role of His-Purkinje conduction system pacing (HPCSP) in reversing adverse remodeling and improving clinical outcomes in PICM patients. Methods: A comprehensive literature search was performed across PubMed, Embase, Cochrane Library, and ClinicalTrials.gov through January 2025. Studies were included if they evaluated outcomes in patients with PICM who had been chronically paced in the right ventricle and subsequently upgraded to HPCSP. Key endpoints included changes in left ventricular ejection fraction (LVEF), New York Heart Association (NYHA) functional class. Results: Six studies comprising 144 patients were included. Over an average follow-up of 17.9 ± 10.5 months, significant improvement in LVEF was observed, increasing from 35 ± 8% prior to upgrade to 48 ± 12% following HPCSP (P < 0.001). Similarly, NYHA class improved from a baseline of 2.7 ± 0.8 to 1.9 ± 0.8 (P < 0.001), indicating meaningful symptomatic relief. Conclusion: Upgrading to His-Purkinje conduction system pacing is a safe and effective strategy in patients with PICM. It offers significant improvements in cardiac function and quality of life by restoring physiologic electrical activation. HPCSP represents a promising alternative to BiVP in this population and should be considered in clinical decision-making for pacing upgrades.
Abstract 4372102: Bempedoic Acid Lowers LDL-C and Reduces Risk of Major Cardiovascular Events in Hypercholesterolemia: Meta-Analysis of 13 Randomized Controlled Trials
Daid, Simranpreet Singh, Sharma, Arundhati , Choudhary, Khushal, Sharma, Anubhuti

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4372102 Get It

Introduction: Hypercholesterolemia drives atherosclerotic cardiovascular disease. Bempedoic acid (BA) lowers low-density-lipoprotein cholesterol (LDL-C) by inhibiting ATP-citrate-lyase, providing a non-statin option for patients who need additional lipid control. Hypothesis: We expected BA to improve atherogenic lipids and major adverse cardiovascular events (MACE) without raising cardiovascular (CV) mortality and with an acceptable safety profile. Aims: To measure the pooled effect of BA on (1) LDL-C, (2) non-HDL-C, (3) high-sensitivity C-reactive protein (hsCRP) and to compare clinical outcomes for (4) MACE, (5) CV mortality, and (6) hyperuricemia versus placebo. Methods: A systematic search of PubMed, Embase, MEDLINE, Google Scholar and ClinicalTrials.gov through 1 April 2025 identified randomized controlled trials (RCTs) of BA versus placebo in adults with hypercholesterolemia. Data were extracted into a spreadsheet, and analyses were performed with RevMan 5.4. Results: 13 RCT's with 22345 patients met the inclusion criteria. BA produced robust lipid and inflammatory improvements. LDL-C fell by 24.3 % (95 % CI −27.8 to −20.9), non-HDL-C by 19.8 % (95 % CI −25.0 to −14.6), and hsCRP by 26.7 % (95 % CI −39.6 to −13.7). These changes translated into a 19 % relative reduction in MACE (RR 0.81, 95 % CI 0.68–0.96), while CV mortality was unchanged (RR 0.87, 95 % CI 0.53–1.43). As anticipated, hyperuricemia risk almost doubled with BA (RR 1.93, 95 % CI 1.75–2.14). Conclusion: BA consistently lowers LDL-C, non-HDL-C and systemic inflammation and reduces MACE without affecting CV mortality. The main safety concern is higher hyperuricemia, which appears manageable with monitoring. These findings support BA as an effective add-on therapy for patients who are statin-intolerant or need further lipid reduction, while highlighting the need for longer trials to assess mortality benefits and long-term safety.
Abstract 4365204: HP- 13 CMRAnalyst : A MATLAB Application for Dynamic Cardiac Metabolic Imaging Analysis Usin
Jessen, Michael E. , Sharma, Gaurav , Jagtap, Jaidip , Peltz, Matthias , Malloy, Craig R.

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4365204 Get It

Introduction: Hyperpolarized [1- 13 C] pyruvate magnetic resonance imaging (HP- 13 C MRI) enables real-time, noninvasive assessment of myocardial metabolism. While the technique is increasingly applied in cardiac research, dedicated tools for standardized analysis remain limited. We developed HP- 13 CMRAnalyst , a MATLAB-based application that supports dynamic 13 C data processing through semi-automated segmentation, time-course extraction, and metabolic ratio mapping (Figure 1A). Hypothesis: An integrated platform combining multi-frame 13 C data import, cine co-registration, multi-segment analysis, and voxel-level ratio mapping facilitates reproducible quantification of myocardial metabolism. Methods: HP- 13 CMRAnalyst was implemented in MATLAB App Designer and distributed as an .mlappinstall package. It accepts DICOM or NIfTI dynamic pyruvate, lactate, and bicarbonate images (∼3 s resolution; ≤ 60 s)(Figure 1B). Cine-registered T 1 -weighted images guide AHA 17-segment LV segmentation on short axis (SAX) and long axis (LAX) views (Figure 1C). A time slider displays metabolite overlays. Peak intensities are extracted per segment to compute bicarbonate/lactate and bicarbonate/pyruvate ratios. Pixel-wise ratio maps are exported as CSV, MATLAB struct, and PDF summaries. Results: Eight subjects (n = 4 healthy; n = 4 coronary artery disease [CAD]), each imaged pre- and post-CABG (total n = 12 datasets; age 55 ± 12 years), were processed in < 5 min per dataset on a standard desktop (MATLAB R2024b). Semi-automated versus manual segmentation agreement was high (Dice 0.89–0.93). Inter-observer variability for segmental bicarbonate/(bicarbonate + lactate) ratios were minimal biases < 0.005 and limits of agreement within ± 0.083 across all observer pairs (Figure 1D). Ratio maps qualitatively revealed regional metabolic heterogeneity. Automated reports accurately reflected metadata and segmental summaries. The GUI, logs, and summary files streamline standardized processing. Conclusions: HP- 13 CMRAnalyst delivers a rapid (< 5 min), reproducible framework for dynamic HP- 13 C MRI analysis. By combining semi-automated segmentation and pixel-level ratio mapping with low inter-observer variability, this platform may accelerate adoption of 13 C metabolic imaging in human cardiac research.
Abstract 4371215: ANGPTL3 Targeting Monoclonal Antibodies Lead to Robust Reductions in LDL-C, Triglycerides, ApoB, and Non-HDL-C in Dyslipidemic Patients: A Meta-Analysis of 5 Randomized Controlled Trials
Daid, Simranpreet Singh, Sharma, Arundhati , Pannu, Sagal, Asnani, Heena , Bhanushali, Karan B. , Choudhary, Khushal, Sharma, Anubhuti , Sharma, Saurabh

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4371215 Get It

Introduction: Dyslipidemia remains a major driver of cardiovascular disease. Monoclonal antibodies (mAb) that block angiopoietin-like protein 3 (ANGPTL3) lower atherogenic lipids by a mechanism distinct from statins. Earlier evidence centred on the Evinacumab. A new trial now evaluate the investigational antibody SHR-1918. Hypothesis: We hypothesized that treatment with ANGPTL3 mAbs whether evinacumab or SHR-1918 would significantly improve lipid parameters compared to placebo without increasing adverse events. Aims: To Quantify the pooled effect of ANGPTL3 mAbs on low-density lipoprotein cholesterol (LDL-C), Triglycerides, apolipoprotein B (ApoB) and non-high-density lipoprotein cholesterol (non-HDL-C) and Compare efficacy and safety between Evinacumab and SHR-1918 subgroups. Methods: A systematic search of Pubmed, Google Scholar MEDLINE, Embase, and ClinicalTrials.gov untill 1 April 2025 was done and relevant randomised controlled trials (RCT's) comparing ANGPTL3 mAbs with placebo in dyslipidaemic patients were included. Data was extracted on spreadsheet and Data analysis was done in RevMan 5.4. Results: 5 RCT's comprising of 603 patients met inclusion criteria. The pooled analysis showed marked reductions in atherogenic lipids with ANGPTL3 monoclonal antibodies versus placebo, including low-density lipoprotein cholesterol (SMD = –2.73, 95 % CI –4.16 to –1.31, P < 0.001), triglycerides (SMD = –3.54, 95 % CI –4.71 to –2.37, P < 0.001), apolipoprotein B (SMD = –1.98, 95 % CI –2.97 to –1.00, P < 0.001) and non-HDL-C (SMD = –2.89, 95 % CI –4.00 to –1.78, P < 0.001). Sub-group analyses demonstrated directionally consistent lipid lowering for both evinacumab and the newer agent SHR-1918. Adverse-event due to treatment evaluation revealed no significant increase in Adverse events due to treatment (RR = 1.05, 95 % CI 0.87 to 1.27, P = 0.63) or serious events (RR = 1.37, 95 % CI 0.54 to 3.44, P = 0.49), indicating good overall tolerability. Conclusion: monoclonal antibodies targeting ANGPTL3 encompassing both evinacumab and the newer agent SHR-1918 consistently reduced LDL-C, triglycerides, and related lipid markers with a favourable tolerability profile. Further large, long-term studies are needed to fully establish their safety, clinical effectiveness, and potential to improve cardiovascular outcomes.